Abivax (NASDAQ:ABVX) Sees Unusually-High Trading Volume After Analyst Upgrade

Abivax SA Sponsored ADR (NASDAQ:ABVX) shares saw unusually-strong trading volume on Wednesday after Jefferies Financial Group upgraded the stock from a hold rating to a buy rating. Jefferies Financial Group now has a $158.00 price target on the stock, up from their previous price target of $108.00. Approximately 1,194,238 shares traded hands during trading, a decline of 23% from the previous session’s volume of 1,553,965 shares.The stock last traded at $136.7350 and had previously closed at $133.26.

A number of other analysts also recently commented on ABVX. Leerink Partners boosted their target price on Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a research report on Tuesday. Guggenheim reaffirmed a “buy” rating on shares of Abivax in a research note on Tuesday. Morgan Stanley decreased their price objective on shares of Abivax from $145.00 to $132.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 2nd. Citizens Jmp lifted their target price on shares of Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Fourteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $144.46.

Key Abivax News

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Updated Phase 2/3 data for obefazimod showed meaningful clinical benefit in hard-to-treat ulcerative colitis patients and reinforced the maintenance safety database, easing earlier concerns about cancer signals. Article title
• Positive Sentiment: Reuters and other outlets highlighted that the drug showed benefit in relapsed and non-responding patients, supporting the view that the therapy could address a difficult-to-treat market. Article title
• Positive Sentiment: Several analysts turned more constructive, including Jefferies upgrading ABVX to buy and Leerink raising its price target, which can reinforce bullish sentiment after the data readout. Article title
• Neutral Sentiment: Abivax temporarily halted and then resumed trading in Paris while it finalized a large ADS offering, signaling a financing move rather than a change in the underlying drug data. Article title
• Negative Sentiment: The company launched and then upsized a large public offering of American Depositary Shares, which could dilute existing shareholders even as it strengthens the balance sheet. Article title

Hedge Funds Weigh In On Abivax

Institutional investors and hedge funds have recently bought and sold shares of the stock. GHP Investment Advisors Inc. raised its stake in Abivax by 155.6% during the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares during the period. WPG Advisers LLC raised its position in shares of Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after buying an additional 253 shares during the period. Assetmark Inc. boosted its holdings in Abivax by 41.5% in the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock valued at $99,000 after acquiring an additional 260 shares during the last quarter. SmartHarvest Portfolios LLC boosted its holdings in Abivax by 11.6% in the first quarter. SmartHarvest Portfolios LLC now owns 2,696 shares of the company’s stock valued at $300,000 after acquiring an additional 280 shares during the last quarter. Finally, Personal CFO Solutions LLC increased its stake in Abivax by 10.5% during the first quarter. Personal CFO Solutions LLC now owns 3,027 shares of the company’s stock worth $337,000 after acquiring an additional 288 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Stock Performance

The company has a market capitalization of $10.92 billion, a PE ratio of -26.34 and a beta of 0.69. The business has a fifty day moving average price of $111.04 and a 200 day moving average price of $117.42.

Abivax (NASDAQ:ABVX) last issued its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. Research analysts forecast that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.